Bayer seeks USFDA nod for Gadoquatrane for contrast enhanced magnetic resonance imaging of CNS Ruchika Sharma17 Jun 2025 12:44 PM ISTBerlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its...
Bayer, Broad Institute extend research collaboration to develop new cardiovascular therapies Ruchika Sharma11 Jun 2025 1:15 PM ISTBerlin: Bayer and the Broad Institute have extended their research collaboration of 10 years by an additional five years, to further advance...
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Bayer Ruchika Sharma9 Jun 2025 10:00 AM ISTBerlin: Bayer has announced results of the Phase II CONFIDENCE study, demonstrating that simultaneous initiation of finerenone (Kerendia)...
Bayer arm secures exclusive worldwide rights to develop, commercialize clinical-stage WRN Inhibitor Ruchika Sharma8 Jun 2025 10:00 AM ISTSan Diego: Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of...
Bayer Prostate Cancer Drug Nubeqa gains third regulatory win from USFDA Ruchika Sharma4 Jun 2025 2:59 PM ISTBerlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor (ARi) Nubeqa...
Bayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone Dr. Divya Colin31 May 2025 5:56 PM ISTNew Delhi: Bayer Pharmaceutical has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Bayer Sevabertinib gets USFDA Priority Review status for HER2-mutant non-small cell lung cancer Ruchika Sharma29 May 2025 11:15 AM ISTBerlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational compound sevabertinib...
Bayer begins Phase I study with GIRK4 inhibitor for atrial fibrillation Ruchika Sharma25 May 2025 11:00 AM ISTBerlin: Bayer has announced initiation of a Phase I clinical trial with BAY 3670549, an investigational highly selective G-protein-coupled...
Bayer-Regeneron Eylea 8 mg approved in China for wet age-related macular degeneration Ruchika Sharma22 May 2025 3:30 PM ISTBerlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for Eylea 8...
Bayer Jivi gets USFDA approval for pediatric patients 7 years of age and older with hemophilia A Ruchika Sharma21 May 2025 2:50 PM ISTThe approval is based on data from the Alfa-PROTECT and PROTECT Kids studies.
Bayer seeks Japenese nod for Aflibercept to treat macular edema following retinal vein occlusion Ruchika Sharma11 May 2025 1:45 PM ISTBerlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of aflibercept 8 mg...
Bayer begins Phase I study targeting GPC3 with alpha radiopharmaceutical in advanced hepatocellular carcinoma patients Ruchika Sharma4 May 2025 12:30 PM ISTBerlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha...
